Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals /:
Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety an...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Santa Monica, Calif. :
RAND Institute for Civil Justice,
2013.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies. |
| Beschreibung: | 1 online resource (xx, 96 pages) : illustrations |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9780833079916 0833079913 |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBU-ocn849912765 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 130607s2013 caua ob 000 0 eng d | ||
| 040 | |a MERUC |b eng |e pn |c MERUC |d E7B |d OCLCO |d JSTOR |d OCLCF |d N$T |d COO |d OCLCO |d YDXCP |d EBLCP |d DEBSZ |d OCLCQ |d LOA |d AGLDB |d OCLCQ |d COCUF |d OCLCQ |d MOR |d CCO |d PIFAG |d ZCU |d MERUC |d OCLCQ |d LND |d VFL |d U3W |d STF |d WRM |d OCLCQ |d NRAMU |d OCLCA |d ICG |d VT2 |d EZ9 |d AU@ |d ERL |d OCLCQ |d ICN |d DKC |d CNTRU |d OCLCQ |d NJT |d OCLCQ |d UKCRE |d BOL |d VLY |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 857365412 |a 968289216 |a 988510839 |a 991964754 |a 1008958987 |a 1037774795 |a 1038660862 |a 1045493559 |a 1107371882 |a 1114384057 |a 1115093526 |a 1153497049 |a 1162400445 |a 1228606001 | ||
| 020 | |a 9780833079916 |q (electronic bk.) | ||
| 020 | |a 0833079913 |q (electronic bk.) | ||
| 035 | |a (OCoLC)849912765 |z (OCoLC)857365412 |z (OCoLC)968289216 |z (OCoLC)988510839 |z (OCoLC)991964754 |z (OCoLC)1008958987 |z (OCoLC)1037774795 |z (OCoLC)1038660862 |z (OCoLC)1045493559 |z (OCoLC)1107371882 |z (OCoLC)1114384057 |z (OCoLC)1115093526 |z (OCoLC)1153497049 |z (OCoLC)1162400445 |z (OCoLC)1228606001 | ||
| 037 | |a 22573/ctt297h2m |b JSTOR | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a KF1297.D7 |b G37 2013eb | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a LAW113000 |2 bisacsh | |
| 072 | 7 | |a LAW098000 |2 bisacsh | |
| 072 | 7 | |a BUS |x 070000 |2 bisacsh | |
| 082 | 7 | |a 338.4761510973 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Garber, Steven. | |
| 245 | 1 | 0 | |a Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / |c Steven Garber. |
| 260 | |a Santa Monica, Calif. : |b RAND Institute for Civil Justice, |c 2013. | ||
| 300 | |a 1 online resource (xx, 96 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 340 | |g polychrome. |2 rdacc |0 http://rdaregistry.info/termList/RDAColourContent/1003 | ||
| 347 | |a text file |2 rdaft |0 http://rdaregistry.info/termList/fileType/1002 | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Ch. 1. Introduction -- ch. 2. Conceptual framework for the analyses -- ch. 3. The legal and institutional settings -- ch. 4. Pharmaceutical mass torts during the 1990s and 2000s -- ch. 5. Preemption of pharmaceutical failure-to-warn claims -- ch. 6. Incentives stemming from other litigation affecting safety and effectiveness -- ch. 7. In conclusions. | |
| 505 | 0 | |a Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency. | |
| 505 | 8 | |a Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims. | |
| 505 | 8 | |a Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability. | |
| 505 | 8 | |a Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown. | |
| 505 | 8 | |a CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury. | |
| 520 | |a Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Products liability |x Drugs |x Economic aspects |z United States. | |
| 650 | 0 | |a Pharmaceutical industry |z United States. | |
| 650 | 6 | |a Responsabilité du fait des produits |x Médicaments |x Aspect économique |z États-Unis. | |
| 650 | 6 | |a Industrie pharmaceutique |z États-Unis. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Industries |x General. |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Products liability |x Drugs |x Economic aspects |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 776 | 0 | 8 | |i Print version: |a Garber, Steven. |t Economic Effects of Product Liability and Other Litigation Involving the Safety and Effectiveness of Pharmaceuticals. |d Santa Monica : RAND Corporation, ©2013 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBU |q FWS_PDA_EBU |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=608717 |3 Volltext |
| 936 | |a BATCHLOAD | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL1365205 | ||
| 938 | |a ebrary |b EBRY |n ebr10678757 | ||
| 938 | |a EBSCOhost |b EBSC |n 608717 | ||
| 938 | |a YBP Library Services |b YANK |n 10406250 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBU | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBU-ocn849912765 |
|---|---|
| _version_ | 1816796909442957312 |
| adam_text | |
| any_adam_object | |
| author | Garber, Steven |
| author_facet | Garber, Steven |
| author_role | |
| author_sort | Garber, Steven |
| author_variant | s g sg |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | K - Law |
| callnumber-label | KF1297 |
| callnumber-raw | KF1297.D7 G37 2013eb |
| callnumber-search | KF1297.D7 G37 2013eb |
| callnumber-sort | KF 41297 D7 G37 42013EB |
| callnumber-subject | KF - United States |
| collection | ZDB-4-EBU |
| contents | Ch. 1. Introduction -- ch. 2. Conceptual framework for the analyses -- ch. 3. The legal and institutional settings -- ch. 4. Pharmaceutical mass torts during the 1990s and 2000s -- ch. 5. Preemption of pharmaceutical failure-to-warn claims -- ch. 6. Incentives stemming from other litigation affecting safety and effectiveness -- ch. 7. In conclusions. Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency. Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims. Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability. Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown. CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury. |
| ctrlnum | (OCoLC)849912765 |
| dewey-full | 338.4761510973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4761510973 |
| dewey-search | 338.4761510973 |
| dewey-sort | 3338.4761510973 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07131cam a2200685 a 4500</leader><controlfield tag="001">ZDB-4-EBU-ocn849912765</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cn|||||||||</controlfield><controlfield tag="008">130607s2013 caua ob 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MERUC</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">MERUC</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCO</subfield><subfield code="d">JSTOR</subfield><subfield code="d">OCLCF</subfield><subfield code="d">N$T</subfield><subfield code="d">COO</subfield><subfield code="d">OCLCO</subfield><subfield code="d">YDXCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">LOA</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">COCUF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">MOR</subfield><subfield code="d">CCO</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">LND</subfield><subfield code="d">VFL</subfield><subfield code="d">U3W</subfield><subfield code="d">STF</subfield><subfield code="d">WRM</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NRAMU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">ICG</subfield><subfield code="d">VT2</subfield><subfield code="d">EZ9</subfield><subfield code="d">AU@</subfield><subfield code="d">ERL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">ICN</subfield><subfield code="d">DKC</subfield><subfield code="d">CNTRU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NJT</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UKCRE</subfield><subfield code="d">BOL</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">857365412</subfield><subfield code="a">968289216</subfield><subfield code="a">988510839</subfield><subfield code="a">991964754</subfield><subfield code="a">1008958987</subfield><subfield code="a">1037774795</subfield><subfield code="a">1038660862</subfield><subfield code="a">1045493559</subfield><subfield code="a">1107371882</subfield><subfield code="a">1114384057</subfield><subfield code="a">1115093526</subfield><subfield code="a">1153497049</subfield><subfield code="a">1162400445</subfield><subfield code="a">1228606001</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780833079916</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0833079913</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)849912765</subfield><subfield code="z">(OCoLC)857365412</subfield><subfield code="z">(OCoLC)968289216</subfield><subfield code="z">(OCoLC)988510839</subfield><subfield code="z">(OCoLC)991964754</subfield><subfield code="z">(OCoLC)1008958987</subfield><subfield code="z">(OCoLC)1037774795</subfield><subfield code="z">(OCoLC)1038660862</subfield><subfield code="z">(OCoLC)1045493559</subfield><subfield code="z">(OCoLC)1107371882</subfield><subfield code="z">(OCoLC)1114384057</subfield><subfield code="z">(OCoLC)1115093526</subfield><subfield code="z">(OCoLC)1153497049</subfield><subfield code="z">(OCoLC)1162400445</subfield><subfield code="z">(OCoLC)1228606001</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">22573/ctt297h2m</subfield><subfield code="b">JSTOR</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">KF1297.D7</subfield><subfield code="b">G37 2013eb</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">LAW113000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">LAW098000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">BUS</subfield><subfield code="x">070000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">338.4761510973</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garber, Steven.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals /</subfield><subfield code="c">Steven Garber.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Santa Monica, Calif. :</subfield><subfield code="b">RAND Institute for Civil Justice,</subfield><subfield code="c">2013.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xx, 96 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="340" ind1=" " ind2=" "><subfield code="g">polychrome.</subfield><subfield code="2">rdacc</subfield><subfield code="0">http://rdaregistry.info/termList/RDAColourContent/1003</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rdaft</subfield><subfield code="0">http://rdaregistry.info/termList/fileType/1002</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Ch. 1. Introduction -- ch. 2. Conceptual framework for the analyses -- ch. 3. The legal and institutional settings -- ch. 4. Pharmaceutical mass torts during the 1990s and 2000s -- ch. 5. Preemption of pharmaceutical failure-to-warn claims -- ch. 6. Incentives stemming from other litigation affecting safety and effectiveness -- ch. 7. In conclusions.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Products liability</subfield><subfield code="x">Drugs</subfield><subfield code="x">Economic aspects</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Responsabilité du fait des produits</subfield><subfield code="x">Médicaments</subfield><subfield code="x">Aspect économique</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS</subfield><subfield code="x">Industries</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Products liability</subfield><subfield code="x">Drugs</subfield><subfield code="x">Economic aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Garber, Steven.</subfield><subfield code="t">Economic Effects of Product Liability and Other Litigation Involving the Safety and Effectiveness of Pharmaceuticals.</subfield><subfield code="d">Santa Monica : RAND Corporation, ©2013</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBU</subfield><subfield code="q">FWS_PDA_EBU</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=608717</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="936" ind1=" " ind2=" "><subfield code="a">BATCHLOAD</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL1365205</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10678757</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">608717</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">10406250</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| geographic | United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq |
| geographic_facet | United States |
| id | ZDB-4-EBU-ocn849912765 |
| illustrated | Illustrated |
| indexdate | 2024-11-26T14:49:10Z |
| institution | BVB |
| isbn | 9780833079916 0833079913 |
| language | English |
| oclc_num | 849912765 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xx, 96 pages) : illustrations |
| psigel | ZDB-4-EBU |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | RAND Institute for Civil Justice, |
| record_format | marc |
| spelling | Garber, Steven. Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / Steven Garber. Santa Monica, Calif. : RAND Institute for Civil Justice, 2013. 1 online resource (xx, 96 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier polychrome. rdacc http://rdaregistry.info/termList/RDAColourContent/1003 text file rdaft http://rdaregistry.info/termList/fileType/1002 Includes bibliographical references. Ch. 1. Introduction -- ch. 2. Conceptual framework for the analyses -- ch. 3. The legal and institutional settings -- ch. 4. Pharmaceutical mass torts during the 1990s and 2000s -- ch. 5. Preemption of pharmaceutical failure-to-warn claims -- ch. 6. Incentives stemming from other litigation affecting safety and effectiveness -- ch. 7. In conclusions. Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency. Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims. Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability. Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown. CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury. Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies. English. Products liability Drugs Economic aspects United States. Pharmaceutical industry United States. Responsabilité du fait des produits Médicaments Aspect économique États-Unis. Industrie pharmaceutique États-Unis. MEDICAL Pharmacology. bisacsh BUSINESS & ECONOMICS Industries General. bisacsh Pharmaceutical industry fast Products liability Drugs Economic aspects fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq Print version: Garber, Steven. Economic Effects of Product Liability and Other Litigation Involving the Safety and Effectiveness of Pharmaceuticals. Santa Monica : RAND Corporation, ©2013 FWS01 ZDB-4-EBU FWS_PDA_EBU https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=608717 Volltext |
| spellingShingle | Garber, Steven Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / Ch. 1. Introduction -- ch. 2. Conceptual framework for the analyses -- ch. 3. The legal and institutional settings -- ch. 4. Pharmaceutical mass torts during the 1990s and 2000s -- ch. 5. Preemption of pharmaceutical failure-to-warn claims -- ch. 6. Incentives stemming from other litigation affecting safety and effectiveness -- ch. 7. In conclusions. Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency. Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims. Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability. Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown. CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury. Products liability Drugs Economic aspects United States. Pharmaceutical industry United States. Responsabilité du fait des produits Médicaments Aspect économique États-Unis. Industrie pharmaceutique États-Unis. MEDICAL Pharmacology. bisacsh BUSINESS & ECONOMICS Industries General. bisacsh Pharmaceutical industry fast Products liability Drugs Economic aspects fast |
| title | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / |
| title_auth | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / |
| title_exact_search | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / |
| title_full | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / Steven Garber. |
| title_fullStr | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / Steven Garber. |
| title_full_unstemmed | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / Steven Garber. |
| title_short | Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals / |
| title_sort | economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals |
| topic | Products liability Drugs Economic aspects United States. Pharmaceutical industry United States. Responsabilité du fait des produits Médicaments Aspect économique États-Unis. Industrie pharmaceutique États-Unis. MEDICAL Pharmacology. bisacsh BUSINESS & ECONOMICS Industries General. bisacsh Pharmaceutical industry fast Products liability Drugs Economic aspects fast |
| topic_facet | Products liability Drugs Economic aspects United States. Pharmaceutical industry United States. Responsabilité du fait des produits Médicaments Aspect économique États-Unis. Industrie pharmaceutique États-Unis. MEDICAL Pharmacology. BUSINESS & ECONOMICS Industries General. Pharmaceutical industry Products liability Drugs Economic aspects United States |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=608717 |
| work_keys_str_mv | AT garbersteven economiceffectsofproductliabilityandotherlitigationinvolvingthesafetyandeffectivenessofpharmaceuticals |